FocalTherics, formerly known as EDAP TMS S.A. (FOCL), a medical technology company, announced Tuesday that it has entered into an agreement with MellingMedical, an SBA-verified Service-Disabled Veteran-Owned Small Business, to expand access to the Focal One Robotic High-Intensity Focused Ultrasound (HIFU) system for veterans with prostate cancer.
The company plans to expand the availability of Focal One across federal healthcare providers, making the prostate treatment technology accessible to veterans and active-duty military personnel throughout the U.S. Department of Veterans Affairs (VA) and Department of Defense healthcare systems.
Prostate cancer care has been a key area of federal focus in recent years, as veterans are diagnosed with prostate cancer at nearly twice the rate of the general population, and the disease accounts for approximately 30% of cancer diagnoses among men in the Veterans Health Administration.
Through MellingMedical's VA Federal Supply Schedule, the agreement is expected to provide access to incision-free, radiation-free robotic focal therapy as a treatment option across the veteran healthcare system.
Chris Melling, Founder and Chief Executive Officer of MellingMedical, said, "This non-invasive treatment approach offers patients the possibility of maintaining their quality of life while effectively treating their condition."
FOCL is currently trading at $4.71, down 0.72%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.